Mini Review

Published on 31 Jul 2023

Cell-based medicinal products approved in the European Union: current evidence and perspectives

in Drugs Outcomes Research and Policies

Stefania Bellino
Anna La Salvia
Maria Francesca Cometa
Rosanna Botta

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1200808

11,739 views
6 citations

Original Research

Published on 27 Jul 2023

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

in Drugs Outcomes Research and Policies

Yin Shi
Di Xiao
Shuishi Li
Shao Liu
Yu Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1198585

1,910 views
1 citation

Original Research

Published on 26 Jul 2023

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer

in Drugs Outcomes Research and Policies

Tingting Lu
Yufan Huang
Zhongjie Cai
Wangchun Lin
Xiaoxiao Chen
Ruijia Chen
Yingying Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1171302

2,060 views
1 citation

Original Research

Published on 20 Jul 2023

Public awareness regarding the manufacturer provided information about medicine usage, safety, and adverse drug reactions in Balochistan, Pakistan

in Drugs Outcomes Research and Policies

Gullab Khan
Noman Haq
Nafees Ahmad
Aqeel Nasim
Asma Javaid
Mujhammad Saood
Riffat Yasmin
Maria Tahir
Sohail Riaz
Zeeshan Danish

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1190741

2,443 views
3 citations

Original Research

Published on 20 Jul 2023

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States

in Drugs Outcomes Research and Policies

Wenjie Liu
Gengwei Huo
Peng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1163381

3,249 views
1 citation

Original Research

Published on 20 Jul 2023

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing

in Drugs Outcomes Research and Policies

Yena Gan
Fenghao Shi
He Zhu
Sheng Han
Duoduo Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1241130

2,300 views
2 citations

Original Research

Published on 14 Jul 2023

Six years’ experience and trends of serum 25-hydroxy vitamin D concentration and the effect of vitamin D3 consumption on these trends

in Drugs Outcomes Research and Policies

László Horváth
Sara Mirani
Michael Magdy Fahmy Girgis
Szilvia Rácz
Ildikó Bácskay
Harjit Pal Bhattoa
Béla E. Tóth

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1232285

2,283 views
3 citations

Review

Published on 13 Jul 2023

Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements

in Drugs Outcomes Research and Policies

Jeffrey M. Muir
Amruta Radhakrishnan
Andreas Freitag
Ipek Ozer Stillman
Grammati Sarri

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1197259

3,228 views
5 citations

Original Research

Published on 13 Jul 2023

Using PIM-Taiwan, PRISCUS, and Beers criteria to assess potentially inappropriate medication use among older adults with 90-day rehospitalization: a population-based study in Taiwan

in Drugs Outcomes Research and Policies

Kun-Pin Hsieh
Ru-Yu Huang
Yi-Hsin Yang
Pei-Shan Ho
Kuang-Peng Chen
Chun-Liong Tung
Ya-Lan Chu
Jui-Hsiu Tsai

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1194537

2,151 views

Systematic Review

Published on 13 Jul 2023

Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis

in Drugs Outcomes Research and Policies

Qiong Huang
Minling You
Weijuan Huang
Jian Chen
Qinming Zeng
Longfeng Jiang
Xiuben Du
Xusheng Liu
Ming Hong
Jing Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1050412

4,252 views
3 citations

Original Research

Published on 13 Jul 2023

Development and validation of pharmaceutical care barriers scale in Chinese hospitals: a cross-sectional survey

in Drugs Outcomes Research and Policies

Liangjiang Chen
Nan Yang
Yuankai Huang
Xiaoyu Xi

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1194901

2,113 views
1 citation

Original Research

Published on 12 Jul 2023

Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records

in Drugs Outcomes Research and Policies

Md Muntasir Zitu
Shijun Zhang
Dwight H. Owen
Chienwei Chiang
Lang Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1218679

2,716 views
5 citations

Original Research

Published on 12 Jul 2023

Adherence, belief, and knowledge about oral anticoagulants in patients with bioprosthetic heart valve replacement: a cross-sectional study

in Drugs Outcomes Research and Policies

Yun-Xia Ni
Lu-Lu Liu
Huang Feng
Zhi Li
Chao-Yi Qin
Miao Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1191006

2,244 views
1 citation

Original Research

Published on 11 Jul 2023

Identification of high-risk patients for referral through machine learning assisting the decision making to manage minor ailments in community pharmacies

in Drugs Outcomes Research and Policies

Noelia Amador-Fernández
Shalom I. Benrimoj
Victoria García-Cárdenas
Miguel Ángel Gastelurrutia
Emma L. Graham
Rubén Palomo-Llinares
Julia Sánchez-Tormo
Vicente J. Baixauli Fernández
Elena Pérez Hoyos
Javier Plaza Zamora

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1105434

2,322 views
1 citation

Original Research

Published on 10 Jul 2023

Unknown adverse drug reactions from spontaneous reports in a hospital setting: characterization, follow-up, and contribution to the pharmacovigilance system

in Drugs Outcomes Research and Policies

Francesca Filippi-Arriaga
Cristina Aguilera
Elena Guillén
Lucía Bellas
Eulàlia Pérez
Lourdes Vendrell
Antònia Agustí
Gloria Cereza

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1211786

2,969 views

Opinion

Published on 03 Jul 2023

Multiple myeloma: challenges with deciding the optimal sequencing strategy

in Drugs Outcomes Research and Policies

Anushka Walia
Alyson Haslam
Jordan Tuia
Vinay Prasad

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1231720

4,180 views
2 citations

Navigation group

Articles

Cell-based medicinal products approved in the European Union: current evidence and perspectives

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer

Public awareness regarding the manufacturer provided information about medicine usage, safety, and adverse drug reactions in Balochistan, Pakistan

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing

Six years’ experience and trends of serum 25-hydroxy vitamin D concentration and the effect of vitamin D3 consumption on these trends

Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements

Using PIM-Taiwan, PRISCUS, and Beers criteria to assess potentially inappropriate medication use among older adults with 90-day rehospitalization: a population-based study in Taiwan

Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis

Development and validation of pharmaceutical care barriers scale in Chinese hospitals: a cross-sectional survey

Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records

Adherence, belief, and knowledge about oral anticoagulants in patients with bioprosthetic heart valve replacement: a cross-sectional study

Identification of high-risk patients for referral through machine learning assisting the decision making to manage minor ailments in community pharmacies

Unknown adverse drug reactions from spontaneous reports in a hospital setting: characterization, follow-up, and contribution to the pharmacovigilance system

Multiple myeloma: challenges with deciding the optimal sequencing strategy